Graticule Asia Macro Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Graticule Asia Macro Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-55,000	Closed	-$7.27M	–	265
2018 Q2	$7.27M	Buy	+55,000	New	+$5.19M	0.46%	45
2017 Q2	–	Sell	-10,350	Closed	-$306K	–	148
2017 Q1	$306K	Hold	10,350	–	–	0.02%	117
2016 Q4	$284K	Sell	10,350 -30,550	-75%	-$1.23M	0.03%	96
2016 Q3	$2.51M	Buy	40,900 +26,200	+178%	+$792K	0.18%	65
2016 Q2	$280K	Buy	14,700 +729	+5%	+$13.5K	0.03%	50
2016 Q1	$273K	Sell	13,971 -25,029	-64%	-$437K	0.02%	77
2015 Q4	$1.5M	Buy	+39,000	New	+$1.26M	0.25%	146

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Graticule Asia Macro Advisors's SRPT Position: Q3 2018 in Review

Graticule Asia Macro Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2018, closing a stake of 55,000 shares — an estimated $7.27M sold.

Graticule Asia Macro Advisors first reported a position in SRPT in Q4 2015 and held it in 7 quarters. The position peaked at $7.27M in Q2 2018. 344 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

Graticule Asia Macro Advisors reported no remaining Sarepta Therapeutics position as of Q3 2018 after selling out during the quarter.
Graticule Asia Macro Advisors sold 55,000 Sarepta Therapeutics shares in Q3 2018, an estimated $7.27M.
Graticule Asia Macro Advisors first reported a position in Sarepta Therapeutics in Q4 2015 and held it in 7 quarters.
Graticule Asia Macro Advisors's Sarepta Therapeutics position peaked at $7.27M in Q2 2018.
344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on Graticule Asia Macro Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.